Encouragingly, a cold-adapted, live-attenuated influenza intranasal vaccine (CAIV-T; Fluenz Tetra, AstraZeneca, London, UK), which was first licensed in 2003, conferred protection with weak or modest serum and mucosa antibody responses (the seroresponse rates of haemagglutination-inhibiting antibodies for influenza A/H1N1, A/H3N2, and B/Harbin were 23%, 33%, and 3%, and the response rates of IgA antibodies in nasal wash were 14%, 32%, and 18%, respectively).28 Here, CD79A is linked to influenza.